Fig. 5

Longitudinal serum apoAI level analysis of 37 patients from the validation cohort according to 90-day outcome. In the survival group (A) and nonsurvival group (B), serum levels of apoAI were measured at baseline, at the 2nd time point (3–7 days) and at the 3rd time point (10–14 days). * P < 0.05